Trial
NCT03227432
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Phase IIWITHDRAWNREGULATORYConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Bristol-Myers Squibb
Condition
Multiple Myeloma
Intervention
Dexamethasone
Why stopped
Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination with IMIDs.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-14